State of systemic inflammation in patients with psoriatic disease of moderate severity of concomitant metabolic syndrome

##plugins.themes.bootstrap3.article.sidebar##

PDF (Українська)
Published: May 20, 2016
DOI: https://doi.org/10.30841/2307-5112.2(64).2016.102527
Keywords:
psoriasis, metabolic syndrome, systemic inflammation,

##plugins.themes.bootstrap3.article.main##

Я. О. Ємченко
ВДНЗ України «Українська медична стоматологічна академія», м. Полтава, Ukraine

Abstract

Clinical and laboratory studies conducted in 40 patients with uncom plicated widespread plaque psoriasis, the stationary phase, the average degree of severity with concomitant metabolic syndrome. Suggest that in patients with concomitant psoriasis MS plays an important role sys temic inflammatory process that is accompanied by the development of insulin resistance (IR), lipid and nitrogen metabolism, regulation of vascular tone. Processes of systemic inflammation and IR in patients with psoriasis and MS may be potential targets of complex therapy.

##plugins.themes.bootstrap3.article.details##

How to Cite
Ємченко, Я. О. (2016). State of systemic inflammation in patients with psoriatic disease of moderate severity of concomitant metabolic syndrome. Family Medicine, (2(64), 148–150. https://doi.org/10.30841/2307-5112.2(64).2016.102527
Issue
No. 2(64) (2016)
Section
Dermatology
Copyright (c) 2020 Я. О. Ємченко

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.

Author Biography

Я. О. Ємченко, ВДНЗ України «Українська медична стоматологічна академія», м. Полтава

Y.A. Yemchenko

References

Беловол А.Н. Дисфункция сосудистого эндотелия у больных псориазом // Укр. журн. дерматол., венерол., косметол. – 2010. – No 1 (36). – С. 17–21.

Писаржевский С.А. Проницаемость эндотелия и атеросклероз // Кардиология. – 2005. – No 12. – С. 27–42.

Ткаченко С.Г., Кондрашова В.Б. Кардиометаболический риск у больных псориазом // Дерматол. та венерол. – 2010. – No 2 (48). – С. 11–17.

Шмакова А.С. Роль липидных нарушений и провоспалительных цитокинов в патогенезе и их коррекция: Автореф. дис. ... канд. мед. наук. – М., 2009. – 18 с.

Chodorowska G, Wojnowska D, Juszkiewicz Borowiec M (2004) C reactive protein and alpha2 macroglobulin plasma activity in medium severe and severe psoriasis. J Eur Acad Dermatol Venerol 18:180–183.

Henseler T, Schmitt Rau K. A comparison between BSA, PASI, PLASI and SAPASI as measures of disease severity and improvement by therapy in patients with psoriasis // Int J Dermatol. 2008; 47(10):1019–23.

Hotamisligil Gs (2006) Inflammation and metabolic disorders. Nature 444:860–867.

Hansson GI (2005) Inflammation, atherosclerosis and coronary artery disease. N Engl J Med 52:1685–1695.

Ludwig RJ, Schultz JE, Boehncke W H et al (2004) Activated, not resting, platelets increase leukocyte rolling in urine skin utilizing a distinct set of adhesion molecules. J Invest Dermatol 122:830–836.

Mallbris L, Granath F, Hamsten A, Stahle M (2006) Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 54:614–621.

Pereira M.G. Dyadic adjustment, family coping, body image, quality of life and psychological morbidity in patients with psoriasis and their partners./ M.G. Pereira, L. Brito., T. Smith // Int. J. Behav. Med. – 2011 – Jun 25.

Rocha Pereira P, Santos Silva A, Rebelo I et al (2004) The inflammatory respons in mild and in severe psoriasis. Br J Dermatol 150:917–928.

Reich K. The concept of psoriasis as a systemic in?ammation: implications for disease management. JEADV 2012, 26 (Suppl. 2), 3–11.

Schfer T (2006) Epidemiology of psoriasis – review and the German perspective. Dermatology 212: 327–337.

Sommer D., Jenisch M., Suchan M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis // Arch. Dermatol. Res. – 2006. – Vol. 298, No 7. – P. 321–328.

Späh F. Inflammation in atheroscle rosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach // Br. J. Dermatol. – 2008. – Vol. 159, Suppl 2. – Р. 10–17.

Sabbat R., Philips S., Hoflich C. Immunopathogenesis of psoriasis // Exp. Dermatol. – 2007. – Vol. 16, No 9. – P. 779–798.

Wu Y. Prevalence of cardiovascular risk factors and other comorbidities among psoriasis patients // J. Am. Acad. Dermatol. – 2007. – Vol. 191, No 9. – Р. 23–27.